PL1753434T5 - Ulepszony roztwór do oczu bimatoprostu - Google Patents

Ulepszony roztwór do oczu bimatoprostu

Info

Publication number
PL1753434T5
PL1753434T5 PL06738208T PL06738208T PL1753434T5 PL 1753434 T5 PL1753434 T5 PL 1753434T5 PL 06738208 T PL06738208 T PL 06738208T PL 06738208 T PL06738208 T PL 06738208T PL 1753434 T5 PL1753434 T5 PL 1753434T5
Authority
PL
Poland
Prior art keywords
ophthalmic solution
bimatoprost ophthalmic
enhanced
enhanced bimatoprost
solution
Prior art date
Application number
PL06738208T
Other languages
English (en)
Other versions
PL1753434T3 (pl
Inventor
Chin-Ming Chang
James N. Chang
Rhett M. Schiffman
R. Scott Jordan
Joan-En Chang-Lin
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36613401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1753434(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL1753434T3 publication Critical patent/PL1753434T3/pl
Publication of PL1753434T5 publication Critical patent/PL1753434T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL06738208T 2005-03-16 2006-03-14 Ulepszony roztwór do oczu bimatoprostu PL1753434T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/083,261 US7851504B2 (en) 2005-03-16 2005-03-16 Enhanced bimatoprost ophthalmic solution
EP06738208.5A EP1753434B2 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution
PCT/US2006/009124 WO2006101839A2 (en) 2005-03-16 2006-03-14 Enhanced bimatoprost ophthalmic solution

Publications (2)

Publication Number Publication Date
PL1753434T3 PL1753434T3 (pl) 2009-09-30
PL1753434T5 true PL1753434T5 (pl) 2018-05-30

Family

ID=36613401

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06738208T PL1753434T5 (pl) 2005-03-16 2006-03-14 Ulepszony roztwór do oczu bimatoprostu

Country Status (22)

Country Link
US (10) US7851504B2 (pl)
EP (1) EP1753434B2 (pl)
JP (3) JP5367946B2 (pl)
KR (2) KR101177598B1 (pl)
CN (2) CN102240292B (pl)
AR (1) AR055050A1 (pl)
AT (1) ATE431152T1 (pl)
AU (1) AU2006227757B2 (pl)
BR (1) BRPI0607447B1 (pl)
CA (1) CA2585691C (pl)
DE (1) DE602006006762D1 (pl)
DK (1) DK1753434T4 (pl)
ES (1) ES2324058T5 (pl)
IL (1) IL185744A (pl)
MX (1) MX2007011300A (pl)
NO (1) NO337190B1 (pl)
NZ (1) NZ560788A (pl)
PL (1) PL1753434T5 (pl)
RU (1) RU2363471C2 (pl)
TW (1) TWI399207B (pl)
WO (1) WO2006101839A2 (pl)
ZA (1) ZA200707246B (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2011087790A1 (en) * 2009-12-22 2011-07-21 Allergan, Inc. Triple combination for lowering intraocular pres sure
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
KR101820184B1 (ko) * 2010-07-29 2018-01-18 알러간, 인코포레이티드 방부제가 없는 비마토프로스트 및 티몰롤 용액
AU2011282679A1 (en) * 2010-07-29 2013-03-07 Allergan, Inc. Preservative free bimatoprost solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
EA201301332A1 (ru) * 2011-05-27 2014-06-30 Рациофарм Гмбх ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
RU2474426C1 (ru) * 2011-12-26 2013-02-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Простамиды и их аналоги, обладающие нейрозащитным действием
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US9308165B2 (en) * 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
GR1008483B (el) 2013-12-23 2015-05-12 Rafarm Α.Ε.Β.Ε., Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9776330B2 (en) 2014-04-30 2017-10-03 The Boeing Company Crawler robot and supporting platform
US9486917B2 (en) * 2014-04-30 2016-11-08 The Boeing Company Mobile automated assembly tool for aircraft structures
US10017277B2 (en) 2014-04-30 2018-07-10 The Boeing Company Apparatus, system, and method for supporting a wing assembly
US10118714B2 (en) 2014-04-30 2018-11-06 The Boeing Company System and method for positioning an automated assembly tool relative to a structure
US10000298B2 (en) 2014-04-30 2018-06-19 The Boeing Company Metrology system for positioning assemblies
US10427254B2 (en) 2014-04-30 2019-10-01 The Boeing Company Flexible manufacturing for aircraft structures
US9708079B2 (en) 2014-04-30 2017-07-18 The Boeing Company Mobile automated overhead assembly tool for aircraft structures
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
PL3103439T3 (pl) * 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
US11242367B2 (en) 2016-08-12 2022-02-08 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
EP4374851B1 (en) 2016-12-23 2026-04-15 Novaliq GmbH Ophthalmic composition for treatment of dry eye disease
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
USD841152S1 (en) 2017-06-27 2019-02-19 Monica S. Naylor Eye drop container
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
SG11202007860XA (en) 2018-03-28 2020-09-29 Novaliq Gmbh Pharmaceutical composition comprising timolol
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
WO2020178672A1 (en) * 2019-03-06 2020-09-10 Mankind Pharma Ltd. Ophthalmic composition of bimatoprost
WO2020252057A1 (en) * 2019-06-10 2020-12-17 Visus Therapeutics, Inc. Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
US20220249514A1 (en) 2019-06-28 2022-08-11 Regeus Limited Liability Company Remedy for hair growth enhancing
CA3156433A1 (en) 2019-10-31 2021-05-06 Patrizia Chetoni Bimatoprost 0.01% solution compositions for the treatment of ocular hypertension
IT201900024961A1 (it) 2019-12-20 2021-06-20 Rafarm Uk Ltd Formulazioni di bimatoprost in soluzione allo 0,01% per il trattamento dell'ipertensione oculare
AU2020419590A1 (en) 2019-11-15 2022-06-30 Silk Technologies, Ltd. Stable formulations of silk-derived protein
US11786538B2 (en) 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
TW202333662A (zh) 2021-11-10 2023-09-01 美商偉視醫療股份有限公司 增強抗老花眼效果之卡巴可(carbachol)調配物
US12064440B2 (en) 2022-03-21 2024-08-20 Somerset Therapeutics, Llc Ophthalmic gel compositions of bimatoprost and timolol and associated methods
US12128054B2 (en) 2022-10-26 2024-10-29 Famygen Life Sciences, Inc. Aqueous pharmaceutical compositions of prostaglandins

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304907A (en) 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
JPS4969636A (pl) 1972-11-07 1974-07-05
GB1402035A (en) 1972-12-07 1975-08-06 Ici Ltd Cyclopentane derivatives
FR2239458A1 (en) 1973-07-31 1975-02-28 Aries Robert Prostaglandin amides - with antilipolytic, gonadotrophic, luteolytic, hypotensive and other activities associated with prostaglandins
US4183870A (en) 1974-01-26 1980-01-15 May & Baker Limited Cyclopentane derivatives
NL7605381A (nl) 1975-05-26 1976-11-30 Schering Ag Werkwijze voor het bereiden van prostaanderi- vaten en werkwijze voor het bereiden van een geneesmiddel met prostaglandinewerking.
US4081478A (en) 1975-12-29 1978-03-28 The Upjohn Company 2-Decarboxy-2-amino-methyl-PGF.sub.α compounds
US4128577A (en) 1975-12-29 1978-12-05 The Upjohn Company 15-Methyl- and 16-phenoxy-PGF2 α, amides
US4032576A (pl) 1976-01-08 1977-06-28
US4055602A (en) 1976-01-08 1977-10-25 The Upjohn Company 2-Decarboxy-2-hydroxy-methyl-5-oxa-17-phenyl-18,19,20-trinor-PGF-analogs
IL51877A (en) 1976-06-01 1981-09-13 Carlo Erba Sa -nor-16-benzyl or phenoxy-13,14-dehydro-prostaglandins and process for their preparation
US4123441A (en) 1976-09-22 1978-10-31 The Upjohn Company Enlarged-hetero-ring prostacyclin analogs
DE2715838A1 (de) 1977-04-05 1978-10-19 Schering Ag Neue prostanderivate und verfahren zu ihrer herstellung
US4100192A (en) 1977-04-18 1978-07-11 The Upjohn Company Inter-phenylene-PG amides
US4163758A (en) 1977-09-09 1979-08-07 Sagami Chemical Research Center 2-Nitroethylcyclopentane compounds and process for preparing the same
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
CA1141663A (en) 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
US4543353A (en) 1981-11-27 1985-09-24 Farmitalia Carlo Erba S.P.A. Ester and amide derivatives of 13,14-didehydro prostaglandins
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
JPS591463A (ja) 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
DE3371199D1 (en) 1982-08-24 1987-06-04 Teijin Ltd Novel 6-nitroprostaglandin derivatives, process for production thereof, and use thereof
JPS61126069A (ja) 1984-11-21 1986-06-13 Res Dev Corp Of Japan プロスタグランジン誘導体
JPH0611715B2 (ja) 1986-03-17 1994-02-16 花王株式会社 経皮吸収促進剤およびこれを含有する外用剤
US4824857A (en) 1986-05-16 1989-04-25 Yasumasa Goh Use of prostaglandin D2 -active substances
WO1990002553A1 (en) 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
TW224942B (pl) 1990-04-04 1994-06-11 Adka Ueno Kk
US5270049A (en) 1990-11-09 1993-12-14 Allergan, Inc. 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives
IT1256824B (it) * 1992-05-14 1995-12-21 Varian Spa Unita' rivelatrice di elio perfezionata.
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
IT1313610B1 (it) 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020035148A1 (en) 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
WO2002087564A1 (en) 2001-04-28 2002-11-07 The Regents Of The University Of California Class of glaucoma drugs to enhance aqueous humor outflow and lower intra-ocular pressure
US6743439B1 (en) 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
US6743493B2 (en) * 2001-09-11 2004-06-01 Ward-Kraft, Inc. Composite form with imprintable magnetic card
US20040029771A1 (en) 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
JP4836401B2 (ja) 2002-04-01 2011-12-14 ロート製薬株式会社 眼科用組成物
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040079671A1 (en) 2002-08-29 2004-04-29 Paramita Bandyopadhyay Medicinal product packaging
CA2707068A1 (en) 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050049311A1 (en) 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050276867A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US9241918B2 (en) 2005-03-16 2016-01-26 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
ES2820837T3 (es) 2006-07-10 2021-04-22 Esbatech Alcon Biomed Res Unit Anticuerpos scFv que pasan las capas epitelial y/o endotelial

Also Published As

Publication number Publication date
JP5899267B2 (ja) 2016-04-06
KR20120068051A (ko) 2012-06-26
IL185744A0 (en) 2008-01-06
US8338479B2 (en) 2012-12-25
TW200700070A (en) 2007-01-01
US20120142783A1 (en) 2012-06-07
RU2363471C2 (ru) 2009-08-10
US8586630B2 (en) 2013-11-19
US8278353B2 (en) 2012-10-02
EP1753434B2 (en) 2017-12-27
WO2006101839A2 (en) 2006-09-28
US8772338B2 (en) 2014-07-08
US8933120B2 (en) 2015-01-13
DE602006006762D1 (de) 2009-06-25
ZA200707246B (en) 2008-09-25
NZ560788A (en) 2010-12-24
BRPI0607447A2 (pt) 2009-09-01
HK1104211A1 (en) 2008-01-11
US20130203854A1 (en) 2013-08-08
KR20070113292A (ko) 2007-11-28
US20120142782A1 (en) 2012-06-07
US20160250225A1 (en) 2016-09-01
US20130102678A1 (en) 2013-04-25
RU2007133919A (ru) 2009-04-27
IL185744A (en) 2015-09-24
ES2324058T3 (es) 2009-07-29
CN102240292B (zh) 2018-08-07
ES2324058T5 (es) 2018-05-22
US8299118B2 (en) 2012-10-30
DK1753434T4 (en) 2018-03-05
JP2008511539A (ja) 2008-04-17
EP1753434A2 (en) 2007-02-21
EP1753434B1 (en) 2009-05-13
DK1753434T3 (da) 2009-08-03
JP5367946B2 (ja) 2013-12-11
US20110124737A1 (en) 2011-05-26
BRPI0607447B1 (pt) 2022-09-27
MX2007011300A (es) 2007-10-05
US20140100287A1 (en) 2014-04-10
CA2585691A1 (en) 2006-09-28
WO2006101839A3 (en) 2006-12-07
CN102240292A (zh) 2011-11-16
JP2014144983A (ja) 2014-08-14
JP2011148827A (ja) 2011-08-04
CA2585691C (en) 2009-05-19
NO337190B1 (no) 2016-02-08
CN101137383B (zh) 2011-06-15
US20150087713A1 (en) 2015-03-26
NO20074390L (no) 2007-10-15
AU2006227757B2 (en) 2011-07-14
PL1753434T3 (pl) 2009-09-30
US20060211770A1 (en) 2006-09-21
KR101177598B1 (ko) 2012-08-27
ATE431152T1 (de) 2009-05-15
CN101137383A (zh) 2008-03-05
US20090149546A1 (en) 2009-06-11
US7851504B2 (en) 2010-12-14
JP5563515B2 (ja) 2014-07-30
US8309605B2 (en) 2012-11-13
TWI399207B (zh) 2013-06-21
AU2006227757A1 (en) 2006-09-28
AR055050A1 (es) 2007-08-01

Similar Documents

Publication Publication Date Title
IL185744A0 (en) Enhanced bimatoprost ophthalmic solution
AU307469S (en) Eyeglasses
PL1988865T3 (pl) Układ kontaktowy z rogówką
AU303738S (en) Eyeglasses
AU309889S (en) Eyeglasses
ZAA200501698S (en) Eyeglasses
ZAA200501697S (en) Eyeglasses
ZAA200501696S (en) Eyeglasses
AU307465S (en) Eyeglasses
AU307470S (en) Eyeglasses
EP1932054A4 (en) GLASSES
ZAA200501694S (en) Eyeglasses
ZAA200501699S (en) Eyeglasses
IL186681A0 (en) Ophthalmic display
AU307595S (en) Eyeglasses
GB0521432D0 (en) Descender
GB2432919B (en) Swimmimg goggles
GB2443100B (en) Spectacles
AU308209S (en) Headgear
PL384182A1 (pl) Ulepszony oftalmiczny roztwór bimatoprostu
GB0624116D0 (en) Frames
GB0516730D0 (en) Eye model
GB0512724D0 (en) Spectacles
PL115418U1 (en) Spectacles
AU304205S (en) Sunglasses